Figure 5. Cdk5 expression, generation of p25, its kinase activity, and release of arachidonic acid and prostaglandin E2 synthesis by astrocytes exposed to MPP+ and TFP5 treatment. A, The image shows a blot with the expression of Cdk5 in control versus MPP+ (10 μm) along with MPP+ (10 μm) versus MPP+ (10 μm) plus TFP5 and SCP treatment in the protein lysate of astrocytes. B, Bar diagram showing densitometric analysis of Cdk5 expression over β-actin used as a standard for control, MPP+ (10 μm), MPP+ (10 μm) + TFP5 and MPP+ (10 μm) + SCP, respectively. C, The bar diagram represents Cdk5 activity in the astrocyte protein lysate with control versus MPP+ (10 μm) and MPP+ (10 μm) versus MPP+ (10 μm) + TFP5. D, The expression pattern of p35 and p25 in control, MPP+ (10 μm), MPP+ (10 μm) + TFP5, and MPP+ (10 μm) + SCP, respectively. β-Actin was used as a standard. E, The blot representing the expression pattern of cPLA2 in control, MPP+ (10 μm), MPP+ (10 μm) + TFP5, and MPP+ (10 μm) + SCP, respectively. F, The densitometric graph showing cPLA2 expression over β-actin of the above blot. G, The bar graph showing fold changes in cPLA2 activity in astrocyte lysate of control versus MPP+ (10 μm) and MPP+ (10 μm) versus MPP+ (10 μm) + TFP5. H, The scatter plot showing 3H-arachidonic acid release from control astrocytes along with MPP+ (10 μm), MPP+ (10 μm) + TFP5, and MPP+ (10 μm) + SCP. I, The bar graph showing prostaglandin E2 synthesis in control versus MPP+ (10 μm) and MPP+ (10 μm) versus MPP+ (10 μm) + TFP5 along with MPP+ (10 μm) + SCP as the standard for inhibitor treatment. Data are presented as the mean ± SEM, and analysis was performed using one-way ANOVA and Bonferroni’s test; n = 3. *p < 0.05, **p < 0.01, ***p < 0.001, not significant (ns).